DDInter1676 DDInter1063
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or
Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol).
Levosalbutamol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Beclomethasone dipropionate
Levosalbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Levosalbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Levosalbutamol {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Levosalbutamol may cause a minor interaction that can limit clinical effects when taken with Beclomethasone dipropionate
Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Levosalbutamol may lead to a major life threatening interaction when taken with Ribociclib